This rearrangement, found in approximately 50% of prostate cancers, results in a gene fusion, TMPRSS2:Erg, which places ERG expression under the transcriptional control of androgen and oestrogen receptors [54]. The gene discussed is ERG; the disease is prostate carcinoma.